Mark Kroll retired, in 2005, as CTO (Chief Technology Officer) and Sr. VP from St. Jude Medical, Inc.'s main division which is the world's second largest manufacturer of cardiac rhythm management products. St. Jude was twice named as a "Top 50" performing large company by BusinessWeek during this tenure. Dr. Kroll is now a corporate director of Haemonetics (NYSE:HAE), Taser International (NASD:TASR) NewCardio (NWCI).
Dr. Kroll lectures annually for the UCLA Anderson School Creativity and Innovation in the Organization program. He is also an adjunct full professor of Biomedical Engineering at California Polytechnic University; and at the University of Minnesota.
Dr. Kroll received his B.S. in Mathematics, and his M.S. and Ph.D. in Electrical Engineering from the University of Minnesota. He also received his M.B.A. from the University of St. Thomas.
Research specialty is the effects of electricity on the human body. Discoverer of the "burping" effect explaining biphasic defibrillation waveforms. Holds over 300 issued U.S. patents. Honored by U.S. Patent and Trademark Office as prolific inventor. Received the Career Achievement Award in 2010 by the Engineering in Medicine and Biology Society which is the highest international award in biomedical engineering.
Dr. Kroll is a senior member of IEEE, has been listed in Who's Who In Science and Engineering since 1992, and awarded "Fellow" recognition by the American College of Cardiology. He is a Fellow of the Heart Rhythm Society, co-editor of 4 books and written over 200 papers, book chapters, and abstracts.
Dr. Kroll has lectured in over 30 countries on topics including defibrillation, invention process, electrical weapon safety, and medical device startups. He is the most prolific inventor of medical devices in the world. In addition, all ICDs sold have at least one licensed Kroll patent. Over 1 million patients have had devices licensing his patents implanted in them.